ECO Day 2: Lilly MAINTAIN dual publication, Viking VK2735 oral 12.2%, Wegovy Pill OASIS 4 21.6% early responders, ORION Wegovy vs Foundayo ITC, PepGen DM1.
Read digest →ECO 2026 opens: Wegovy 7.2 mg 28% early responders, CagriSema body composition, Foundayo UAE, Tonix Q1, Entera EB613, Oncopeptides Pepaxti EMA.
Read digest →Hims Q1 $608M, MBX once-monthly + STEADI PBH proof-of-concept, Viking VK2735 + Ascletis multi-program ECO, Padova STEP 65+ semaglutide 15.4%, LUNA18 TIDES.
Read digest →Lilly $4.5B Lebanon Indiana investment, Amylyx avexitide expanded access, Nature brain reward circuit paper, Health Canada 2nd generic semaglutide, ASC30 ECO.
Read digest →Foundayo Week 4 IQVIA, Merck enlicitide biocatalytic Science paper, Rhythm Q1 IMCIVREE $60.1M + EMANATE miss, Vertex VX-670 DM1, PolyPeptide credit.
Read digest →Crinetics Q1 Palsonify $10.3M, Zealand Q1 + $700M petrelintide milestone, AstraZeneca eleglipron Phase 2b wins, Entrada DMD positive topline, Foley legal memo.
Read digest →Nature TransCODE peptideins paper, Novo Q1 sub-detail (Wegovy 65% new-Rx, CagriSema co-formulation cut), Jefferies pushback, Lisata-Kuva amendment, Lilly quintuple agonist.
Read digest →Novo Q1 prints Wegovy pill at $354M (2× consensus), tightens guidance; Barclays + Cantor + BofA hike LLY targets; BMC DualPep-ALO hair peptide; ITM-11 PDUFA August 28.
Read digest →Novo's Wegovy pill hit 721K Q1 prescriptions ahead of May 6 print, Drexel Q&A on peptide safety, Nature GLP-1 umbrella review, Pfizer Q1 + 20 obesity trials.
Read digest →Foundayo single liver FAERS case rocks LLY before Lilly + RBC defend, Biomea T1D C-peptide data, Immutep eftilagimod to ASCO, CordenPharma Boulder $500M.
Read digest →Novo retires Rybelsus brand for Ozempic Pill, Manchester Nature Comms penicillin biosynthesis, Ozempic Face data, Roche ENITH Phase 3, Wegovy pill hits 113K scripts.
Read digest →Lilly retatrutide TRANSCEND T2D1 reads out, Amgen MariTide Phase 3 detail at Q1, Mount Sinai liver-detargeted mRNA cancer vaccines, BioVaxys MVP-S to ASCO 2026.
Read digest →Novo unveils Ozempic pill for US adults with T2D plus WW Med+ and GoodRx channels, Lilly stock jumps 6.11% post-Q1, Foundayo Week 3 hits 5,612 scripts, Utah's PapB enzyme cyclizes GLP-1-like peptides.
Read digest →Lilly Q1 revenue jumps 56% as Mounjaro and Zepbound surge, FDA proposes 503B compounding ban for GLP-1s, UTHealth's BLMP6 hits fibulin-4 in metastatic TNBC, and Crinetics wins EU acromegaly approval.
Read digest →Zealand/Roche advance petrelintide to Phase 3; STAT warns RFK peptide push could unleash risky drugs; Rein LTI-03 IPF Phase 2 update; FDA pilots real-time trial monitoring.
Read digest →Boehringer/Zealand Survodutide SYNCHRONIZE-1 hits 16.6% weight loss at 76 weeks; BI 3034701 triple agonist heads to Phase 2; Boston peptide summit opens; Nature peptide papers.
Read digest →Eli Lilly Q1 earnings April 30; C&EN dives into amylin's GLP-1 challenge; AJSM peptide primer for sports medicine; trevogrumab and apitegromab muscle-preservation race.
Read digest →Pre-earnings week ahead — Lilly Apr 30, Novo May 6; Survodutide Phase 3 H1 readout; patient-access analyses post-FDA peptide announcement; AI-designed peptide tooling.
Read digest →